- Prime Medicine to Present at Upcoming Investor Conferences
- Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
- Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
- Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
- Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
More ▼
Key statistics
As of last trade, Prime Medicine Inc (PRME:NMQ) traded at 6.68, 62.53% above the 52 week low of 4.11 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.66 |
---|---|
High | 6.94 |
Low | 6.63 |
Bid | 6.66 |
Offer | 6.68 |
Previous close | 6.89 |
Average volume | 877.06k |
---|---|
Shares outstanding | 120.03m |
Free float | 88.25m |
P/E (TTM) | -- |
Market cap | 777.80m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 19:18 BST.
More ▼